Cardinal Health Inc (CAH) has been highly searched by investors due to its recent activities and performance. The firm has had its shares sold by a number of financial institutions, including Principal Financial Group and NBC Securities, but also saw new holdings purchases from Principal Securities Inc. It has reaffirmed its fiscal 2024 non-GAAP EPS guidance, despite non-renewal of certain contracts.
Argus, a well-respected analyst firm, has lowered CAH's price target to $115.00 as a consequence. The company announced an increase of its dividend to $0.5056, potentially indicating financial stability. Activities indicate an active phase for the firm, purchasing
Specialty Networks and its PPS Analytics platform and launching a pharmaceutical distribution center for over-the-counter products. Despite losing contracts with UnitedHealth's
OptumRX, causing a brief decline in stocks, the company still delivered revenue growth, exceeding analyst EPS forecasts, and raising FY24 guidance. Nevertheless, their stock is regarded as a strong value stock, receiving a consensus recommendation of 'Moderate Buy' by analysts. Even though some shares have sold off, there's been some recent broadening of ownership, and the value seems to be recognized by a higher percentage of institutional investors.
Cardinal Health CAH News Analytics from Tue, 15 Aug 2023 07:00:00 GMT to Sun, 19 May 2024 14:53:57 GMT -
Rating 7
- Innovation 3
- Information 7
- Rumor -3
